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Abstract
Background: In 2004, Ethiopia switched its first-line treatment of uncomplicated Plasmodium falciparum malaria
from sulphadoxine-pyrimethamine to a fixed artemisinin-based combination therapy (ACT), artemether-lumefantrine
(AL). Patient adherence to AL regimen is a major determining factor to achieve the desired therapeutic outcome.
The aim of this study was to measure patient adherence levels to the six-dose AL regimen for the treatment of
uncomplicated P. falciparum malaria and to identify its determinant factors in rural areas of the Tigray region,
Ethiopia
Methods: The study was conducted under routine health service delivery at health posts level. Patients/caregivers
were not informed about their home visit and were traced on the day after they finished the AL regimen. By
combining the response to a structured questionnaire and the tablet count from the blister, adherence level was
classified into three categories: definitely non-adherent, probably non-adherent and probably adherent. Reasons for
being definitely non-adherent were also assessed. For the purpose of examine risk factors, definitely non-adherent
and probably non-adherent was merged into a non-adherent group. Variables found significantly associated (p <
0.05) with the adherence level on the univariate analysis were fitted into a multivariate logistic regression model.
Results: Out of the total initially enrolled 180 patients, 86.1% completed the follow-up. Out of these, 38.7% were
classified as probably adherent, 34.8% as probably non-adherent, and 26.5% were definitely non-adherent. The
most common reasons that definitely non-adherents gave for not taking the full dose were “too many tablets”
(37.3%) and to “felt better before finished the treatment course” (25.5%). The adherence of the patients was
associated with the ownership of a radio (adjusted odd ratio, AOR: 3.8; 95% CI: 1.66-8.75), the belief that malaria
can be treated traditionally (AOR: 0.09; 95% CI: 0.01-0.78) and a delay of more than one day in seeking treatment
after the onset of fever (AOR: 5.39; 95% CI: 1.83-15.88).
Conclusion: The very low adherence to AL found in this study raises serious concerns for the malaria control in
the region. The implementation of a monitoring adherence system is essential to ensure long-term treatment
efficacy.
Background
Despite the current surge of global efforts to scale up
malaria control interventions, the disease is still the
leading cause of morbidity, mortality and economic
losses in sub-Saharan African (SSA) countries [1,2].
Ethiopia is among the countries which contribute most
to this burden. It is estimated that three quarters of the
country’s total area is malarious and an approximated
54 million (68%) of the total population of 80 million
(projected from 2007 census for 2010) live in areas
where they are at risk for the disease [3,4]. Unlike most
parts of SSA where most, if not all, malaria infections
are attributed to Plasmodium falciparum, the parasite
pool in Ethiopia is co-dominated by both P. falciparum
and Plasmodium vivax, sharing approximately 60% and
40% of the cases, respectively [3,5].
In fighting this deadly disease, provision of early diag-
nosis and prompt and effective treatment is the core of
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wide emergence of drug resistance to P. falciparum has
been one of the main barriers to the effectiveness of this
strategy. As result of the 2003 nationwide anti-malarial
in vivo therapeutic efficacy assessment, the country
switched its first-line treatment of uncomplicated P. fal-
ciparum malaria from sulphadoxine-pyrimethamine (SP)
to a fixed artemisinin-based combination therapy
(ACT), artemether-lumefantrine (AL).
Clinical trials have shown that AL is a highly effica-
cious and safe anti-malarial drug [6-11]. However, sev-
eral issues need to be addressed in order to achieve its
desired therapeutic outcome [12]. Among many, patient
adherence to the treatment regimen is a major deter-
mining factor [13,14]. Poor adherence results in sub-
therapeutic drug concentrations which fail to provide a
successful cure. Furthermore, the presence of sub-cura-
tive concentrations of the anti-malarial drug in the
blood will only eliminate the most sensitive parasites,
allowing those that are less sensitive to survive [15].
This contributes to the spread of drug resistant mutant
strains of the malaria parasite [16-18], thus complicating
the treatment scenario.
The need to take unsupervised AL twice daily for
three successive days at the right dose and correct time
interval is challenging and might increase the risk for
poor adherence. Thus, understanding the patient adher-
ence level to this six-dose regimen of AL for the treat-
ment of P. falciparum and identifying its possible
determinant factors is crucial in the provision of effec-
tive malaria treatment. However, despite the fact that
AL is the most widely deployed anti-malarial [1,19], stu-
dies on this treatment are limited, and even the available
studies not only demonstrate different levels of adher-
ence, but also account for different risk factors[20-23].
While high levels of adherence (74-98%) have been
found in most African studies [2,22,24,25], lower levels
have been reported in a study from southern Sudan
(40%) [20]. A literature review on adherence to various
types of anti-malarial drugs identified different defini-
tions, methods, criteria and results. The review also
revealed that the quality and quantity of information
were inadequate and the results varied depending on
the local setting [23]. These variations highlight the
need for local evidence, which is practically lacking in
the Ethiopian context.
T h ea i mo ft h i ss t u d yw a st om e a s u r ep a t i e n ta d h e r -
ence levels to the six-dose AL regimen for the treatment
of uncomplicated P. falciparum and to identify its deter-
minant factors in rural areas of the Tigray region, Ethio-
pia. The results from this research will help to develop
and implement effective communication tools prompt-
ing an effective diagnosis and treatment strategy.
Methods
Study area
Tigray is the northernmost regional state of Ethiopia.
The region has approximately 4.6 million inhabitants
(projected from the 2007 census for 2010); most of
them (80.5%) live in rural areas and depend on subsis-
tence agriculture [4]. As in the rest of Ethiopia, malaria
transmission in Tigray is very seasonal, unstable and
occurs mainly at altitudes below 2,000 m above sea level
(masl). Around 65% of the population in Tigray is at
risk of malaria and the disease is a leading public health
problem in the region [26,27].
The region has a four-tier health delivery system with
the primary health care units (PHCU) at the grass-roots
level. A PHCU includes a health centre and five satellite
health posts [4]. A health post, planned to serve an aver-
age of 5,000 inhabitants, is staffed by two health exten-
sion workers (HEWs). HEWs are high school graduates
with 1 year of training on community-based heath pro-
grammes, including malaria diagnosis and treatment. At
this level, malaria confirmatory diagnosis is done using
rapid diagnostic tests (RDTs) while maintaining a clini-
cal presumptive approach if an RDT is not available. AL
is the drug of choice for treating P. falciparum and
chloroquine is used for non-P. falciparum malaria cases.
Malaria diagnosis and treatment is provided free of
charge [28,29].
Study design and subjects
This study was conducted in three randomly-selected
malarious districts: Raya-azebo and Mereb-leke (1,500-
2,000 masl) and Tahty-adiabo (< 1,000 masl). In all the
three districts, approximately one third of the cases in
the outpatient service were due to malaria [27].
The study was conducted under routine health ser-
vice delivery at health posts level in 2008 in the period
of August-November, the peak malaria transmission
season. Participants were patients who sought treat-
ment from the HEW at the health post or village.
They were included if they were: i) residents of the
catchment area of the health post; ii) positive for the
Paracheck Pf test (P. falciparum-specific RDT device);
iii) older than 2 months of age and iv) patients treated
before noon. Patients receiving the first dose in the
afternoon would require the second and some other
doses at night. Due to the difficulty of relating these
doses time with a natural event, those cases were
excluded Patients were excluded if: i) they exhibited
signs and symptoms of sever disease; ii) there was
already a household member enrolled in the study (no
family was interviewed twice); iii) they were pregnant
mothers in their first trimester and iv)they had taken
AL within the past 2 weeks.
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merator was limited to a maximum of three as tracing
of participants at their homes was difficult and time
consuming. When the number of patients meeting the
i n c l u s i o nc r i t e r i ai n1d a ye x c e e d e dt h r e e ,t h e yw e r e
randomly selected. In the situation where more than
one patient in a day from the same household was trea-
ted, the younger patient was included in order to enrol
as many children as adults. If both were adults, one of
them was randomly selected. Patients/caregivers were
not informed about the visit to their home.
Sample size was calculated based on the assumption
of 25% non-adherence with a precision of 10% and a
design effect of 2 at a 95% confidence interval (CI).
After accounting for the 20% drop-out rate (including
non-replaced immediate spat and/or vomited dose), a
total sample size of 175 participants was required.
Patient management and dose instruction
The AL tablet (Coartem
®,N o v a r t i sP h a r m aA G ,B a s e l ,
Switzerland) is presented in an illustrated patient-
friendly blister pack according to four age groups. The
blister is divided into six compartments, one for each
dose. AL is administered: (i) one tablet (artemether 20
mg/lumefantrine 120 mg) per dose for children > 2
months to 2 years of age; (ii) two tablets per dose for
children three to seven years of age; (iii) three tablets
per dose for children eight to 10 years of age and; (iv)
four tablets per dose for those over 10 years of age [5].
Eligible patients were given the first dose under super-
vision and observed for 30 min. If vomiting occurred
within this period, the dose was repeated and if vomit-
ing persisted, patients were excluded from the study and
referred to the next higher health facility. Instructions
on dosing and frequency/time interval of the remaining
five doses were given to patients/caregivers. The instruc-
tion aimed to achieve the second dose to be taken 8
hours after the first dose and the remaining four doses
at a 12-h interval over the next 2 days. Patient/care-
givers were instructed that if a dose was spat out or
vomited within half an hour after dosing (vomit contains
the drug suspension), a full dose should be re-adminis-
tered with the possibility of refilling/replacing it from
the health post. They were also told that all doses
should preferably be taken with fat-containing food,
such as milk and nuts. In the case of small children,
caregivers were told to dissolve the tablets in water.
They were also advised to visit the next higher health
facility if they felt worse or showed no improvement.
Data collection and patient tracing
A structured questionnaire was developed based on
Fogg et al. and Depoortere et al. [30,31], translated to
the local language and administered in the form of an
interview. Enumerators (HEWs) were trained on: inclu-
sion and exclusion criteria and the use of the question-
naire using mock exercises applying different scenarios.
On day zero, the enrolment day, baseline data including
socio-demographic characteristics, chief complaints, his-
tory of prior medication for the current illness, resi-
dence village (tracing address) and current prescription
was collected. Patients were traced at their home on the
day after they were supposed to have finished the course
of AL (day 3). The first task of the enumerator was to
check the availability of the blister pack and to inspect
for remaining tablets. Then, day-by-day information on
the number of doses, number of tablets in each dose,
time of each dose, reasons for any leftover or missed
dose and the presence or absence of vomiting was col-
lected. If vomiting was present, the estimated time after
intake and action taken was recorded. Reasons for any
leftover or missed dose were also gathered. For patients
under 15 years old, respondents were their parents/care-
givers. Patients/caregivers who were not available in
their home on day 3 were again traced on day four and
if not found, they were considered as lost to follow-up.
During the tracing day, if a patient was found still to be
sick, (s)he was immediately referred to the closest
higher-level health facility.
Definition of adherence and inter-dose interval
By combining the response to the oral interview and the
tablet count from the blister pack, adherence level was clas-
sified into three categories: definitely non-adherent, prob-
ably non-adherent and probably adherent [22,31]. A patient
who had leftover tablet(s) in a blister pack was straightfor-
wardly classified as definitely non-adherent (DNA). When
the blister pack was either missing or empty, but the
patient did not report either taking all doses at the given
time interval (on the correct day or correct timing) or at
the correct amount was classified as probably non-adherent
(PNA). Probably adherent (PA) was a patient who reported
taking all doses, at the given time interval (on the correct
day and correct timing), at the correct amount, and with
no spitting or vomiting within the first 30 min or when
such spat/vomited dose was re-administered.
Patients who did not re-administer any spat or vom-
ited dose which occurred within the first 30 min were
excluded from the analysis. The timing dose given by
the respondent was in association with a natural event,
such as the position of the sun, coffee time, cow milk-
ing, time from church and time of cattle leaving or
entering their shed. Converting theses events to approxi-
mate hours required flexibility. Therefore, the time
interval for the second dose was considered correct if
taken between 8-10 h after the first dose while subse-
quent doses were in the interval of 12 h with a range of
plus/minus 2 h from the preceding dose.
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All collected data were entered and cleaned with Epi-
Info version 3.4.2 (CDC, Atlanta, GA, USA) and then
analysed using Stata 10 (Stata Corp., College Station,
TX, USA) software.
The three levels of adherence were calculated and pre-
sented as proportions. Risk factors of adherence were
examined. For this purpose, definitely non-adherent and
probably non-adherent were merged into a non-adher-
ent group, transforming the outcome variable into bin-
ary. The association between adherence level (the
dependent variable) and several exposure variables (sex,
age group, highest education level in the family, pre-
sence/absence of a radio), history of prior medication
(traditional and/or modern), presence/absence of easily
noticeable symptoms (fever, shiver, vomiting, jaundice),
health improvement after starting treatment, time lag
between the onset of fever and treatment, family size,
presence of a volunteer community health worker
(VCHW) in the family and belief that traditional medi-
cine cures malaria) was first analysed. In a second step,
variables significantly associated (p < 0.05) with the
adherence level were fitted into a multivariate logistic
regression model.
Ethical considerations
The study was approved by the Tigray Health Bureau.
On the day of follow-up (tracing), patients were
informed about the purpose of the study, and partici-
p a n t so rc a r e g i v e r s( f o rp a t i e n t sl e s st h a n1 8y e a r so l d )
were asked to provide verbal consent as majority of the
participants were illiterate.
Results
Patient/guardian general characteristics
Out of the total initially enrolled 180 patients, 86.1% (n
= 155) completed the follow-up. None of the patients
r e f u s e dt ob ei n v o l v e di nt h estudy. Lost to follow-up
(5.6%) was the major reason for exclusion from the ana-
lysis followed by spitting/vomiting a dose within 30 min
with no replacement (5.0%), protocol violation (2.0%)
and severity of illness (one case) (Figure 1). The proto-
col violation occurred in young children (< 11 years old)
and all the lost to follow-up cases were adults aged > 20
years old.
For the patients who completed the follow-up, the
baseline characteristics are shown in Table 1. The
majority (66.5%) were above 10 years old. Nearly all the
patients (93.0%) had a history of fever and 31.6% had an
axillary temperature > 38.5°C on the day of diagnosis.
Since neither a child him/herself nor the caregiver on
his/her behalf could accurately express some of the dis-
ease symptoms, headache, backache, chills/rigors and
joint pain were excluded from the analysis. Symptoms
included were shivering (47.7%), vomiting (43.9%) and
jaundice (5.21%). Around one third of the patients
sought treatment within one to two days (26.4 and
27.1%, respectively) after recognising the symptoms.
Patients reporting prior uptake of either modern medi-
cation (other than AL) or traditional medicine for the
current episodes were 6.5% and 2%, respectively. Eigh-
t e e n( 1 2 . 8 % )p a t i e n t sb e l i e v e dt h a tm a l a r i ac o u l db e
treated traditionally.
In most households (n = 127, 81.9%), either the
patient or his/her parents were illiterate or below grade
5 with only few (n = 24) who had attended medium
school (grades 5-8) with remaining attended high
school. Almost half (45.2%) of the households had a
family size ranging from four to six members, 27.1% had
t h r e eo rm o r ec h i l d r e n<1 0y e a r so l d ,6 . 5 %h a da
VCHW family member and 52.3% owned a radio.
Ninety-six percent felt better in response to the current
treatment.
Adherence level
Out of the total follow-up participants, 94.2% were
traced on day 3 and the rest on day 4. Nearly three
quarters of the patients (73.5%) reported to have com-
pleted the treatment. Out of these, 54 did not correctly
report the dose or the time interval and were classified
as probably non-adherent; the rest (n = 60) were classi-
fied as probably adherent (Figure 1). Errors in frequency
(timing of dose) accounted for almost three quarters of
the probably non-adherent group. Forty-one patients
(26.5%) were found with tablets in the blister and were
thus classified as definitely non-adherent.
I no r d e rt oa s s e s st h ea g ea d h e r e n c ep a t t e r n ,w ec l a s -
sified the subjects into three age groups based on their
ability to make decisions on taking the drug: under 10
years old (completely dependent on their parents), 10-15
years old (partially dependent) and above 15 years old
(independent of their parents). The oldest age group
was mainly PA (40.0%) and PNA (43.8%) while the 10-
15 year old group was overall PA (43.5%) and DNA
(39.1%). The youngest age group was fairly equally dis-
tributed among the three categories.
Definitely non-adherents gave one or more reasons for
not taking any or all of the doses. The most common
reasons were “too many tablets” (37.3%) and to “felt bet-
ter before finished the treatment course” (25.5%). Refu-
sal to take the tablets (7.8%) and “tablets too big to
swallow” (3.9%) were also mentioned as explanations for
not taking the tablets. Other less frequent reasons were
“tablets bitter”, “forgot”, “no improvement” and “kept
for future episodes”. Only one patient/caregiver (2.4%)
claimed not to understand the instructions (Table 2).
Six patients neither reported finishing the doses nor
showed leftover tablets. When asked, the only reasons
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Page 4 of 11they gave were that they shared with others (n = 4) or
kept the medication for future episodes (n = 2).
Of the patients who reported immediate spitting or
vomiting within 30 min (n = 14), only five cases re-
administered the dose; two of them borrowed from their
neighbour and the other three shifted the doses. Despite
the instruction given, no patients replaced the tablets
from the health post.
Four variables were found to be significantly associated
with being adherent in the univariate analysis: the
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n=155 (86.11%)
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n=0 
Follow up 
Total enrolled 
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Total enrolled 
N=196 
Refused conset 
n=0 
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Total enrolled 
N=196 
Follow up 
Total enrolled 
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Refused consent 
n=0 
Protocol violation, 
n=4 (2.04%) 
 
Lost to follow-
up, n=11 
(5.65%) 
Figure 1 Flow diagram showing enrollment, follow-up and adherence level.
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Page 5 of 11ownership of a radio, the belief that malaria cannot be
treated traditionally, a delay of more than 1 day in seeking
treatment after the onset of fever and literacy. When fitted
into the multivariate logistic regression model, the
ownership of a radio (adjusted odd ratio, AOR: 3.8; 95%
CI: 1.66-8.75), the belief that malaria can be treated tradi-
tionally (AOR: 0.09; 95% CI: 0.01-0.78) and a delay of
more than 1 day in seeking treatment after the onset of
Table 1 Patients’ characteristic by adherence level to AL, Tigray, Ethiopia 2008
Patients/guardian characteristic (n = 155) n (%) DNA n = 41 (%) PNA n = 54 (%) PA n = 60 (%)
Sex
Male 74 (47.7) 24 (58.5) 23 (42.6) 27 (45.0)
Female 81 (52.3) 17(41.5) 31 (57.4) 33 (55.0)
Treatment age group
3 months-2 years 7 (4.5) 4 (9.8) 1 (1.9) 2 (3.3)
3-7 years 28 (18.1) 10 (24.4) 5 (9.3) 13 (21.7)
8-10 years 17 (11.0) 5 (12.2) 9 (16.7) 3 (5.0)
> 10 years 103 (66.5) 22 (53.6) 39 (72.0) 42 (70.0)
Age group
≤10 years 52 (33.5) 19 (46.3) 15 (27.8) 18 (30.0)
11-14 years 23 (14.8) 9 (22.0) 4 (7.4) 10 (16.7)
≥15 years 80 (51.6) 13 (31.7) 35 (64.8) 32 (53.3)
Chief complaint (Yes)*
Fever 144 (92.9) 40 (97.6) 48 (88.9) 56 (93.3)
Shiver 74 (47.7) 20 (48.8) 24 (44.4) 30 (50.0)
Vomit 68 (43.9) 22 (53.7) 16 (29.6) 30 (50.0)
Jaundice 8 (5.2) 2 (4.9) 1 (1.8) 5 (8.3)
Axillary temperature (°C) at day zero
= < 37.5 24 (15.5) 6 (14.6) 10 (18.5) 8 (13.3)
37.6-38.5 82 (52.9) 22 (53.7) 30 (55.6) 30 (50.0)
38.6-39.5 49 (31.6) 13 (31.7) 14 (25.9) 22 (36.7)
VCHW in family (Yes) 10 (6.5) 1 (2.4) 5 (9.2) 4 (6.7)
Possession of radio (Yes) 81 (52.3) 8 (19.5) 27 (50.0) 46 (76.7)
Education of patient/caregiver (Illiterate) 127 (81.9) 38 (92.7) 47 (87.0) 42 (70.0)
Prior modern medicine (Yes) 10 (6.5) 4 (9.8) 3 (5.0) 3 (5.6)
Prior traditional medicine (Yes) 3 (1.9) 2 (4.9) 1 (1.9) 0 (0.0)
Belief that malaria treated traditionally (Yes) 18 (12.8) 7 (19.4) 10 (19.6) 1 (1.9)
Response to current treatment (Improved) 148 (95.5) 34 (23.0) 54 (36.5) 60 (40.5)
Days between onset of fever and treatment
1 day 41 (26.4) 9 (22.0) 25 (46.3) 7 (11.7)
2 day 42 (27.1) 7 (17.0) 15 (27.8) 20 (33.3)
3-5 days 72 (46.5) 25 (61.0) 14 (25.9) 33 (55.0)
Family size
1-3 29 (18.7) 9 (22.0) 8 (14.9) 12 (20.0)
4-6 70 (45.2) 19 (46.3) 24 (44.4) 27 (45.0)
> 6 56 (36.1) 13 (31.7) 22 (40.7) 21 (35.0)
Number of children under 10 years**
0 30 (19.7) 9 (22.0) 8 (15.0) 13 (22.4)
1-2 80 (52.6) 17 (41.5) 28 (52.8) 35 (60.3)
> = 3 42 (27.6) 15 (36.6) 17 (32.0) 10 (17.2)
* Row-wise as column-wise presentation is less informative. The figures represent those who reported the particular symptom out of the total cases (N = 155).
**152 families
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(Table 3).
Discussion
Adherence to AL is a capital issue in achieving effective
implementation of the malaria case management strat-
egy. The poor results obtained in this study population
(26.5% were definitely non-adherers) raises great con-
cern. Taking into consideration the probable non-adher-
ent patients, the level of non-adherence could increase
up to 61.3%. Few studies, mostly from African countries,
have specifically assessed the level of adherence to the
six-dose regimen of AL. The level of adherence in these
studies ranged between 74% in Ghana to 98.3% in Tan-
zania [2,22,24,25,32]. However, low levels of adherence
to AL similar to our study (40%) have also been
reported in children aged less than 5 years in southern
Sudan[20]. The only non-African study assessing adher-
ence to AL comes from Bangladesh. This randomized
controlled trial comparing directly observed vs. non-
directly observed treatment (NDOT) obtained 93%
adherence rate in the NDOT group [33]. While the
enormous gap between these studies and ours could be
real, several issues need to be taken into account that
might partly explain these discrepancies.
One first issue relates to the type of context where the
studies were carried out. For instance, in the Ugandan
study [22], the sample was an educated semi-urban
population living in a high endemic malaria area,
whereas our study was placed in a rural setting with a
predominantly illiterate population living in a low trans-
mission setting where cases were managed at rural
health facilities. Populations in high endemic areas are
more aware of malaria and its consequences [34], and
semi-urban populations are also more likely to have bet-
ter access to health information than in rural
settlements
A second issue to consider is the design of the study.
In a study conducted in Tanzania, a level of adherence
to AL of approximately 90% was reported. However,
patients or caregivers were informed that there would
be a follow-up visit, which could influence patient/
caregiver behaviour. In another study from Ghana,
patient follow-up took place between 4 and 14 days
after the initial dose. In such cases, blister pack inspec-
tion for leftover tablets with this lag of time might not
show real adherence. In addition, the close supervision
carried out by the research team could have contributed
to the high level of compliance reported [24].
A third aspect relates to the definition of adherence.
In this study, a very strict definition was used, including
patients who reported taking all doses at the given time
interval (on the correct day and correct timing), at the
correct amount and with no spitting or vomiting within
the first 30 min, or such spat/vomited dose was re-
administered. In some previous studies, the inter-dose
time interval was either not clearly described
[22,25,32,33] or very broadly defined [2]. For instance,
in the study from Ghana (adherence level 92.5%), adher-
ence was based on the description of how AL was given
by the caregivers but no specific information about the
time interval or the correct dose seems to have been
collected [24]. In the study from Zambia, the inter-dose
timing (+/-4 h) was wide compared to this one (+/-2 h),
thus increasing the number of probably adherent
patients [2]. In fact, three fourths of the probably non-
adherent classifications in our study were due to incor-
rect timing.
Several reasons were presented by patients/caregivers
on why they did not finish the treatment course. The
most common reason was “too many tablets” (37.3%).
This concern was mainly expressed by caregivers of chil-
dren less than 15 years old. Parents/caregivers might be
fearful to give many tablets to their small child. Thus,
they might have modified either the dosing or timing or
both and were ultimately found to be non-adherent.
The rapid fever clearance and clinical recovery under
AL treatment seemed to encourage patients to give up
the regimen. “Felt better before finishing the regimen”
was the second reason (25.5%) for not taking all the
tablets. Different studies have also pointed to an
improvement in the condition as the main reason for
treatment discontinuation [14,22,24,33]. Reasons such as
“refused to take”, “bitter”,a n d“too big to swallow” were
restricted to children aged less than 5 years. This indi-
cated that the AL tablets were inconvenient for care-
givers to administer. The current introduction of a
dispersible paediatric formulation of AL might contri-
bute to overcoming this problem [35].
One commonly reported reason for lack of adherence
in many other studies was misunderstanding the
instructions provided by the health care personnel
[31,36]. In the present study, this was low (2.4%). One
potential explanation of this finding might be that the
HEWs were native residents from the area, which could
increase the communication confidence of the patient.
Table 2 Reasons among definitely non-adherent patients
(n = 41) for interrupting the treatment
Why tablet leftover n (%)
Too many tablet) 19 (37.3)
Felt better before treatment course finished 13 (25.5)
Tablet was bitter or forgot or no improvement or keep for
future
12 (23.5)
Refused 4 (7.8)
Tablets too big 2 (3.9)
Don’t understand the instruction 1 (2.0)
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2008
Patient/guardian characteristic Adherent Non-adherent Odd ratio(OR) (95%CI) Adjusted (AOR) (95%CI)
n (%) n %
Sex
Female 27 36.49 47 63.51 1 -
Male 33 40.74 48 59.26 1.12 (0.44-1.60)
Age group
10 years 18 34.62 34 65.38 1
10-15 10 43.48 13 56.52 1.45 (0.53-3.96) -
> = 15 years 32 41.00 48 60.00 1.26 (0.61-2.60) -
Chief complaints
Fever
No 4 36.36 7 63.64 1 -
Yes 56 38.89 88 61.11 1.11 (0.31-3.98)
Shivering
No 30 37.04 51 62.96 1
Yes 30 40.54 44 59.46 1.16 (0.61-2.21) -
Vomiting
No 30 34.48 57 65.52 1 -
Yes 30 44.12 38 55.88 1.5 (0.78-2.88)
Jaundice
No 55 37.41 92 62.59 1
Yes 5 62.50 3 37.50 2.79 (0.64-12.12) -
Axillary temperature (°C) at day zero
≤37.5 8 33.33 16 66.67 1
≥ 37.6 and ≤ 38.4 30 36.59 52 63.41 1.15 (0.44-3.01) -
≥ 38.5 and ≤ 39.5 22 44.90 27 55.10 1.63 (0.59-4.51) -
VCHW in family
No 56 38.62 89 61.38 1 -
Yes 4 40.00 6 60.00 1.06 (0.29-3.92)
Possession of radio
No 14 18.92 60 81.08 1 -
Yes 46 56.79 35 43.21 5.63 (2.72-11.68) 3.82 (1.66-8.75)
Education of patient/caregiver
Illiterate 18 31.58 85 68.42 1
Literate 42 34.29 10 65.71 1.83 (1.15-2.92) 2.27 (0.86-6.01)
Prior modern medicine
No 57 39.31 88 60.69 1
Yes 3 30.00 7 70..00 0.66 (0.18-1.54) .-
Prior traditional medicine
No 60 39.74 92 60.26 - -
Yes 0 0.00 3 100.00 Dropped -
Belief that malaria treated traditionally
No 59 43.09 78 56.91 1
Yes 1 5.56 17 94.44 0.08(0.01-0.60) 0.09 (0.01-0.78)
Response to current treatment
Not improved 0 0 7 100 1
improved 60 40.54 88 59.46 1.15 (0.55-2.40) -
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within the blister packet might have contributed to
understand dosing and inter-dose spacing. On the other
hand, given that the HEWs were in this study providers
and data collectors at the same time, patients might
have been reluctant to report misunderstandings.
Although side-effects have been reported with other
drugs as a reason for not completing the treatment
course [37], this was not the case with AL in the current
study.
Three risk factors were strongly associated with being
adherent: owning a radio, the belief that malaria cannot
be treated traditionally and a delay in treatment seeking.
The Tigray Health Bureau has made an effort to com-
municate health messages on malaria prevention and
control strategies via posters, leaflets, community gath-
erings and radio messages. Radio broadcasting health
messages is a well-known health promotion tool. A pre-
vious study in the area has shown that the ownership of
a radio also increases the knowledge about malaria and
t h ep r a c t i c eo fp r e v e n t i o nm easures, such as the use of
long-lasting insecticidal nets [34]. Those who sought
treatment more than 1 day after the onset of fever were
5.4 times more likely to adhere to the treatment regi-
men than those who sought treatment earlier. This
could be because the more a patient delays the visit, the
more they suffer and the likelihood of treatment-seeking
increases with the severity of symptoms [14]. The delay
in treatment-seeking as promoting factor for adherence
should be interpreted with some caution. Though it
increased adherence, this should be discouraged since it
contradicts with the national and regional goal of 100%
of suspected malaria cases diagnosed and treated within
24 h of the onset of illness [3]. The belief that malaria
can be treated traditionally supported the possibility of
interrupting AL treatment in favour of traditional medi-
cine. Education has been found to be an important risk
factor for adherence in some studies [22,31,33]. How-
ever, in agreement with research from Bangladesh, edu-
cation did not play any role in this study. A probable
explanation would be the high proportion of uneducated
people in this rural area.
This study has also identified some issues of concern.
First, although few, patients reported borrowing/sharing
tablets for replacing vomited doses or keeping them for
future episodes. Second, protocol violations (prescription
did not match the subject’s age), which was seen only in
children, indicated that the fear of “too many tablets”
occurred not only among caregivers, but also among
care providers. Third, despite the recommendation for
early diagnosis and prompt treatment and improved for-
mal health care access as the result of the HEP, only
one-quarter of the patients sought treatment within 1
day of the onset of fever.
Methodological considerations
Certain factors must be considered when interpreting
these results. First, the self-reported method of adher-
ence assessment is open to different biases such as recall
and good-will bias. Particularly the latter can lead to a
lower estimation of the true level of non-adherence as
patients would be more likely to be unwilling to report
missed doses [6,13,20]. The enumerators might also be
resistant to collect negative responses as poor results
might indicate their performance. However, the low
level of adherence in our study seems not to reflect
Table 3 Factors associated with adherence level to AL: univariate and multivariate logistic regression model, Tigray,
2008 (Continued)
Days between onset of fever and treatment
1 day 7 17.07 34 82.93 1
2 day 20 47.62 22 52.38 4.42 (1.60-12-17) 5.03 (1.54-16.32)
3-5 days 33 45.83 39 54.17 4.11 (1.61-10.48 5.40 (1.83-15.88)
Family size
1-3 12 41.38 17 58.62 1
4-6 27 38.57 43 61.43 0.89 (0.37-2.15) -
> 6 21 37.50 35 62.50 0.85 (0.34-2.12) -
Number of children under 10 years old*
0 13 43.33 17 56.67 1 -
1-2 35 43.75 45 56.25 1.02 (0.44-2.37) -
> = 3 10 23.81 32 76.19 0.41 (0.15-1.13) -
Zone/transmission intensity
Below 1000 masl 1
Between 1000-15000 masl 0.61 (0.32-1.17) -
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Page 9 of 11these concerns. Another limitation was that only reasons
for definitely non-adherent (patients with leftover
tablets) were assessed, but not reasons for being prob-
ably non-adherent and probably adherent. Furthermore,
given the poor and rural context of our study, informa-
tion on dose timing could not be collected accurately,
which could have influenced the classification of
patients.
Conclusions
Adherence to recommended malaria drug regimens is a
key determinant of the success of any malaria control
programme. The current study in Tigray has shown
very low adherence to AL. This brought about three ser-
ious concerns: i) the inadequate cure of the patient, ii)
the risk of transmission due to parasite survivors in
non-adherent patients and iii) the development of para-
site resistance. This study has identified some aspects
which the malaria control programme in Tigray should
concentrate on. The use of radios should be promoted
and radio-health messages regarding the importance of
adherence to AL should be intensified. Specific training
on communicating treatment instructions should be car-
ried out with the HEWs. The implementation of a mon-
itoring adherence system is essential to ensure long-
term treatment efficacy.
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